These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

403 related items for PubMed ID: 9544684

  • 21. Imaging of haemodialysis-associated amyloidosis with 123I-serum amyloid P component.
    Nelson SR, Hawkins PN, Richardson S, Lavender JP, Sethi D, Gower PE, Pugh CW, Winearls CG, Oliver DO, Pepys MB.
    Lancet; 1991 Aug 10; 338(8763):335-9. PubMed ID: 1677697
    [Abstract] [Full Text] [Related]

  • 22. Homozygous serum amyloid P component-deficiency does not enhance regression of AA amyloid deposits.
    Usui I, Kawano H, Ito S, Hamada Y, Ishihara T, Maeda S.
    Amyloid; 2001 Jun 10; 8(2):101-4. PubMed ID: 11409030
    [Abstract] [Full Text] [Related]

  • 23. Comparative evaluation of p5+14 with SAP and peptide p5 by dual-energy SPECT imaging of mice with AA amyloidosis.
    Martin EB, Williams A, Richey T, Stuckey A, Heidel RE, Kennel SJ, Wall JS.
    Sci Rep; 2016 Mar 03; 6():22695. PubMed ID: 26936002
    [Abstract] [Full Text] [Related]

  • 24. Diagnostic radionuclide imaging of amyloid: biological targeting by circulating human serum amyloid P component.
    Hawkins PN, Myers MJ, Lavender JP, Pepys MB.
    Lancet; 1988 Jun 25; 1(8600):1413-8. PubMed ID: 2898580
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Comparative analysis of peptide p5 and serum amyloid P component for imaging AA amyloid in mice using dual-isotope SPECT.
    Wall JS, Richey T, Williams A, Stuckey A, Osborne D, Martin E, Kennel SJ.
    Mol Imaging Biol; 2012 Aug 25; 14(4):402-7. PubMed ID: 22042488
    [Abstract] [Full Text] [Related]

  • 27. Studies with radiolabelled serum amyloid P component provide evidence for turnover and regression of amyloid deposits in vivo.
    Hawkins PN.
    Clin Sci (Lond); 1994 Sep 25; 87(3):289-95. PubMed ID: 7955904
    [Abstract] [Full Text] [Related]

  • 28. [Localized or systemic amyloidosis? Value and limitations of Iodine-123 labelled amyloid P component scintigraphy, role of biopsy of minor salivary glands].
    Hachulla E, Wechsler B, Deveaux M, Godeau P, Hatron PY, Devulder B, Janin A, Marchandise X.
    Rev Med Interne; 1994 Mar 25; 15(3):182-5. PubMed ID: 8059132
    [Abstract] [Full Text] [Related]

  • 29. Circulating serum amyloid P component is the precursor of amyloid P component in tissue amyloid deposits.
    Baltz ML, Caspi D, Evans DJ, Rowe IF, Hind CR, Pepys MB.
    Clin Exp Immunol; 1986 Dec 25; 66(3):691-700. PubMed ID: 3568456
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. Quantitative high-resolution microradiographic imaging of amyloid deposits in a novel murine model of AA amyloidosis.
    Wall JS, Kennel SJ, Paulus MJ, Gleason S, Gregor J, Baba J, Schell M, Richey T, O'Nuallain B, Donnell R, Hawkins PN, Weiss DT, Solomon A.
    Amyloid; 2005 Sep 25; 12(3):149-56. PubMed ID: 16194869
    [Abstract] [Full Text] [Related]

  • 32. Use of genetically altered mice to study the role of serum amyloid P component in amyloid deposition.
    Maeda S.
    Amyloid; 2003 Aug 25; 10 Suppl 1():17-20. PubMed ID: 14640037
    [Abstract] [Full Text] [Related]

  • 33. Renal transplantation for amyloid end-stage renal failure-insights from serial serum amyloid P component scintigraphy.
    Gillmore JD, Madhoo S, Pepys MB, Hawkins PN.
    Nucl Med Commun; 2000 Aug 25; 21(8):735-40. PubMed ID: 11039456
    [Abstract] [Full Text] [Related]

  • 34. Micro-imaging of amyloid in mice.
    Wall JS, Paulus MJ, Gleason S, Gregor J, Solomon A, Kennel SJ.
    Methods Enzymol; 2006 Aug 25; 412():161-82. PubMed ID: 17046658
    [Abstract] [Full Text] [Related]

  • 35. Amyloid proteins in pathogenesis of AA amyloidosis.
    Cunnane G.
    Lancet; 2001 Jul 07; 358(9275):4-5. PubMed ID: 11454365
    [No Abstract] [Full Text] [Related]

  • 36. Therapeutic Clearance of Amyloid by Antibodies to Serum Amyloid P Component.
    Richards DB, Cookson LM, Berges AC, Barton SV, Lane T, Ritter JM, Fontana M, Moon JC, Pinzani M, Gillmore JD, Hawkins PN, Pepys MB.
    N Engl J Med; 2015 Sep 17; 373(12):1106-14. PubMed ID: 26176329
    [Abstract] [Full Text] [Related]

  • 37. Potential for imaging cerebral amyloid deposits using 123I-labelled serum amyloid P component and SPET.
    Bornebroek M, Verzijlbergen JF, Haan J, Van Scheyen EJ, Verhoeff NP, Pauwels EK, Roos RA.
    Nucl Med Commun; 1996 Nov 17; 17(11):929-33. PubMed ID: 8971863
    [Abstract] [Full Text] [Related]

  • 38. Repeat doses of antibody to serum amyloid P component clear amyloid deposits in patients with systemic amyloidosis.
    Richards DB, Cookson LM, Barton SV, Liefaard L, Lane T, Hutt DF, Ritter JM, Fontana M, Moon JC, Gillmore JD, Wechalekar A, Hawkins PN, Pepys MB.
    Sci Transl Med; 2018 Jan 03; 10(422):. PubMed ID: 29298867
    [Abstract] [Full Text] [Related]

  • 39.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 40. Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis.
    Kuroda T, Tanabe N, Hasegawa E, Wakamatsu A, Nozawa Y, Sato H, Nakatsue T, Wada Y, Ito Y, Imai N, Ueno M, Nakano M, Narita I.
    Amyloid; 2017 Jun 03; 24(2):123-130. PubMed ID: 28613962
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 21.